{"id":469184,"date":"2021-03-31T17:08:28","date_gmt":"2021-03-31T21:08:28","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=469184"},"modified":"2021-03-31T17:08:28","modified_gmt":"2021-03-31T21:08:28","slug":"medexus-reports-all-medexus-non-executive-directors-choose-rsus-in-lieu-of-cash-fees","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-reports-all-medexus-non-executive-directors-choose-rsus-in-lieu-of-cash-fees\/","title":{"rendered":"Medexus Reports All Medexus Non-Executive Directors Choose RSUs in Lieu of Cash Fees"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">TORONTO, CHICAGO and MONTREAL, March  31, 2021  (GLOBE NEWSWIRE) &#8212; Medexus Pharmaceuticals Inc. (the \u201c<strong>Company<\/strong>\u201d or <strong>\u201cMedexus<\/strong>\u201d) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) is pleased to report that the Company\u2019s non-executive directors were permitted to make a one-time, irrevocable election, to receive restricted share units (\u201cRSUs\u201d) in lieu of cash director fees for the 2021 calendar year and all non-executive directors have made such election.<\/p>\n<p align=\"justify\">The RSUs will be issued in accordance with the Company\u2019s 2018 omnibus equity incentive plan and on the first day following each quarter-end, with the number of RSUs determined by reference to the cash fees that would otherwise be payable to the applicable director, and the volume-weighted average trading price of the Company\u2019s common shares. The RSUs will vest immediately and entitle the applicable holder to receive one common share of the Company at a price of $0.01 per common share.<\/p>\n<p align=\"justify\">\n        <strong>About Medexus Pharmaceuticals Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Medexus is a leading innovative and rare disease company with a strong North American commercial platform. From a foundation of proven best in class products we are building a highly differentiated company with a portfolio of innovative and high value orphan and rare disease products that will underpin our growth for the next decade. The Company\u2019s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology, and allergy. The Company\u2019s leading products are: Rasuvo\u2122 and Metoject\u00ae, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY\u00ae, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B \u2013 a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall\u00ae, an innovative prescription allergy medication with a unique mode of action.<\/p>\n<p align=\"justify\">\n        <strong>For more information, please contact:<\/strong>\n      <\/p>\n<p>Ken d\u2019Entremont, Chief Executive Officer<br \/>Medexus Pharmaceuticals Inc.<br \/>Tel.: 905-676-0003<br \/>E-mail:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7VlDzVWnuyyzwIz0bCOa6QogBH7ba7N4Jri5HAeOVOts0W76D_LTVAXUny4wCX3eFBPEZkC4ppxEA2dujVaXAH7yHiyLMhr-G1DxoeIQAH-Ytl_phbCDjlvozLqukVeW\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">ken.dentremont@medexus.com<\/a><\/p>\n<p>Roland Boivin, Chief Financial Officer<br \/>Medexus Pharmaceuticals Inc.<br \/>Tel.: 514-344-8765<br \/>E-mail:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sNCtGTqlwxfIPpL1VgElzFLmlrA-5jAX-vlaQotsUz1y-E6w-tmYhOjGYrMTNzC9I2lFR923m4oluTZgPqAljtfMqlEhUu9CPjxROOFFqQA=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">roland.boivin@medexus.com<\/a><\/p>\n<p>Investor Relations (U.S.):<br \/>Crescendo Communications, LLC<br \/>Tel: +1-212-671-1020<br \/>Email:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sn38Bl4QnzkVrHpGU8rKw_j0DQzWi_ajQssVgiPNmSrTCFCZ9xGsMKbWOvb1Ox5mb71miAagXMEk6OKBUGSi8MGux1h4V_cEvrK-fG6ob2g=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">mdp@crescendo-ir.com<\/a><\/p>\n<p>Investor Relations (Canada):<br \/>Tina Byers<br \/>Adelaide Capital <br \/>Tel: 905-330-3275<br \/>E-mail:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jEPmD-bVyMKHqvQoteFstfpky42Z_O4Nb6_sMF4CPYLUzj888mCd0OyHaLPsHKgJpeiTUJCToIsh5Jzzrp9Ilg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">tina@adcap.ca<\/a><\/p>\n<p><strong><em>Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/em><\/strong><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTc4MyM0MTAwMjQ0IzIxMjU3ODQ=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/0c6b0a7b-2542-4280-b1f4-f28c35c20fbb\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>TORONTO, CHICAGO and MONTREAL, March 31, 2021 (GLOBE NEWSWIRE) &#8212; Medexus Pharmaceuticals Inc. (the \u201cCompany\u201d or \u201cMedexus\u201d) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) is pleased to report that the Company\u2019s non-executive directors were permitted to make a one-time, irrevocable election, to receive restricted share units (\u201cRSUs\u201d) in lieu of cash director fees for the 2021 calendar year and all non-executive directors have made such election. The RSUs will be issued in accordance with the Company\u2019s 2018 omnibus equity incentive plan and on the first day following each quarter-end, with the number of RSUs determined by reference to the cash fees that would otherwise be payable to the applicable director, and the volume-weighted average trading price of the Company\u2019s common shares. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-reports-all-medexus-non-executive-directors-choose-rsus-in-lieu-of-cash-fees\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Medexus Reports All Medexus Non-Executive Directors Choose RSUs in Lieu of Cash Fees&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-469184","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Medexus Reports All Medexus Non-Executive Directors Choose RSUs in Lieu of Cash Fees - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-reports-all-medexus-non-executive-directors-choose-rsus-in-lieu-of-cash-fees\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Medexus Reports All Medexus Non-Executive Directors Choose RSUs in Lieu of Cash Fees - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TORONTO, CHICAGO and MONTREAL, March 31, 2021 (GLOBE NEWSWIRE) &#8212; Medexus Pharmaceuticals Inc. (the \u201cCompany\u201d or \u201cMedexus\u201d) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) is pleased to report that the Company\u2019s non-executive directors were permitted to make a one-time, irrevocable election, to receive restricted share units (\u201cRSUs\u201d) in lieu of cash director fees for the 2021 calendar year and all non-executive directors have made such election. The RSUs will be issued in accordance with the Company\u2019s 2018 omnibus equity incentive plan and on the first day following each quarter-end, with the number of RSUs determined by reference to the cash fees that would otherwise be payable to the applicable director, and the volume-weighted average trading price of the Company\u2019s common shares. &hellip; Continue reading &quot;Medexus Reports All Medexus Non-Executive Directors Choose RSUs in Lieu of Cash Fees&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-reports-all-medexus-non-executive-directors-choose-rsus-in-lieu-of-cash-fees\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-31T21:08:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTc4MyM0MTAwMjQ0IzIxMjU3ODQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medexus-reports-all-medexus-non-executive-directors-choose-rsus-in-lieu-of-cash-fees\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medexus-reports-all-medexus-non-executive-directors-choose-rsus-in-lieu-of-cash-fees\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Medexus Reports All Medexus Non-Executive Directors Choose RSUs in Lieu of Cash Fees\",\"datePublished\":\"2021-03-31T21:08:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medexus-reports-all-medexus-non-executive-directors-choose-rsus-in-lieu-of-cash-fees\\\/\"},\"wordCount\":432,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medexus-reports-all-medexus-non-executive-directors-choose-rsus-in-lieu-of-cash-fees\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwOTc4MyM0MTAwMjQ0IzIxMjU3ODQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medexus-reports-all-medexus-non-executive-directors-choose-rsus-in-lieu-of-cash-fees\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medexus-reports-all-medexus-non-executive-directors-choose-rsus-in-lieu-of-cash-fees\\\/\",\"name\":\"Medexus Reports All Medexus Non-Executive Directors Choose RSUs in Lieu of Cash Fees - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medexus-reports-all-medexus-non-executive-directors-choose-rsus-in-lieu-of-cash-fees\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medexus-reports-all-medexus-non-executive-directors-choose-rsus-in-lieu-of-cash-fees\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwOTc4MyM0MTAwMjQ0IzIxMjU3ODQ=\",\"datePublished\":\"2021-03-31T21:08:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medexus-reports-all-medexus-non-executive-directors-choose-rsus-in-lieu-of-cash-fees\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medexus-reports-all-medexus-non-executive-directors-choose-rsus-in-lieu-of-cash-fees\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medexus-reports-all-medexus-non-executive-directors-choose-rsus-in-lieu-of-cash-fees\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwOTc4MyM0MTAwMjQ0IzIxMjU3ODQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwOTc4MyM0MTAwMjQ0IzIxMjU3ODQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medexus-reports-all-medexus-non-executive-directors-choose-rsus-in-lieu-of-cash-fees\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medexus Reports All Medexus Non-Executive Directors Choose RSUs in Lieu of Cash Fees\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Medexus Reports All Medexus Non-Executive Directors Choose RSUs in Lieu of Cash Fees - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-reports-all-medexus-non-executive-directors-choose-rsus-in-lieu-of-cash-fees\/","og_locale":"en_US","og_type":"article","og_title":"Medexus Reports All Medexus Non-Executive Directors Choose RSUs in Lieu of Cash Fees - Market Newsdesk","og_description":"TORONTO, CHICAGO and MONTREAL, March 31, 2021 (GLOBE NEWSWIRE) &#8212; Medexus Pharmaceuticals Inc. (the \u201cCompany\u201d or \u201cMedexus\u201d) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) is pleased to report that the Company\u2019s non-executive directors were permitted to make a one-time, irrevocable election, to receive restricted share units (\u201cRSUs\u201d) in lieu of cash director fees for the 2021 calendar year and all non-executive directors have made such election. The RSUs will be issued in accordance with the Company\u2019s 2018 omnibus equity incentive plan and on the first day following each quarter-end, with the number of RSUs determined by reference to the cash fees that would otherwise be payable to the applicable director, and the volume-weighted average trading price of the Company\u2019s common shares. &hellip; Continue reading \"Medexus Reports All Medexus Non-Executive Directors Choose RSUs in Lieu of Cash Fees\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-reports-all-medexus-non-executive-directors-choose-rsus-in-lieu-of-cash-fees\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-31T21:08:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTc4MyM0MTAwMjQ0IzIxMjU3ODQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-reports-all-medexus-non-executive-directors-choose-rsus-in-lieu-of-cash-fees\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-reports-all-medexus-non-executive-directors-choose-rsus-in-lieu-of-cash-fees\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Medexus Reports All Medexus Non-Executive Directors Choose RSUs in Lieu of Cash Fees","datePublished":"2021-03-31T21:08:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-reports-all-medexus-non-executive-directors-choose-rsus-in-lieu-of-cash-fees\/"},"wordCount":432,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-reports-all-medexus-non-executive-directors-choose-rsus-in-lieu-of-cash-fees\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTc4MyM0MTAwMjQ0IzIxMjU3ODQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-reports-all-medexus-non-executive-directors-choose-rsus-in-lieu-of-cash-fees\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-reports-all-medexus-non-executive-directors-choose-rsus-in-lieu-of-cash-fees\/","name":"Medexus Reports All Medexus Non-Executive Directors Choose RSUs in Lieu of Cash Fees - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-reports-all-medexus-non-executive-directors-choose-rsus-in-lieu-of-cash-fees\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-reports-all-medexus-non-executive-directors-choose-rsus-in-lieu-of-cash-fees\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTc4MyM0MTAwMjQ0IzIxMjU3ODQ=","datePublished":"2021-03-31T21:08:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-reports-all-medexus-non-executive-directors-choose-rsus-in-lieu-of-cash-fees\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/medexus-reports-all-medexus-non-executive-directors-choose-rsus-in-lieu-of-cash-fees\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-reports-all-medexus-non-executive-directors-choose-rsus-in-lieu-of-cash-fees\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTc4MyM0MTAwMjQ0IzIxMjU3ODQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTc4MyM0MTAwMjQ0IzIxMjU3ODQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medexus-reports-all-medexus-non-executive-directors-choose-rsus-in-lieu-of-cash-fees\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Medexus Reports All Medexus Non-Executive Directors Choose RSUs in Lieu of Cash Fees"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/469184","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=469184"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/469184\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=469184"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=469184"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=469184"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}